- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07540104
Bloc du plan intercostal postérieur supérieur du muscle dentelé postérieur supérieur versus morphine intrathécale dans la VATs
Comparaison des effets du bloc du plan intercostal postérieur supérieur du serratus antérieur et de la morphine intrathécale sur la douleur postopératoire aiguë chez les patients subissant une chirurgie thoracoscopique vidéo-assistée
This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.
The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.
The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.
Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.
The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.
Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.
This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Samsun
-
Atakent, Samsun, Turquie (Türkiye), 55270
- Ondokuz Mayis University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age between 18 and 75 years
- American Society of Anesthesiologists physical status I to III
- Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy
Exclusion Criteria:
- Refusal to participate
- Pregnancy
- Morbid obesity (body mass index greater than 40 kg per square meter)
- Allergy to study medications
- Neuropsychiatric disorders, cognitive impairment, or inability to communicate
- History of substance abuse
- Active systemic infection or infection at the planned injection site
- Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
- Chronic pain syndrome or ongoing chronic pain treatment
- Emergency surgery or previous ipsilateral VATS or thoracotomy
- Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
- Anticipated need for postoperative mechanical ventilation.
- Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intrathecal Morphine
Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia. |
|
Expérimental: Serratus Posterior Superior Intercostal Plane Block
Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
Délai: 24 hours
|
Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia. |
24 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
Délai: 12 hours
|
Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents |
12 hours
|
|
Postoperative pain scores
Délai: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Time to first patient-controlled analgesia demand
Délai: 24 hours
|
Time from postoperative admission to the first PCA morphine demand. |
24 hours
|
|
Quality of recovery score
Délai: Preoperative baseline, 24 hours postoperatively, and at discharge
|
Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery. |
Preoperative baseline, 24 hours postoperatively, and at discharge
|
|
Postoperative nausea and vomiting
Délai: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Sedation level
Délai: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Respiratory depression
Délai: 24 hours
|
Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute |
24 hours
|
|
Pruritus
Délai: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Block-related complications
Délai: Up to 30 days postoperatively
|
Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions. |
Up to 30 days postoperatively
|
|
Postoperative complications
Délai: 30 days
|
Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications. |
30 days
|
|
Remifentanil consumption
Délai: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Rescue analgesia requirement
Délai: 24 hours
|
Incidence of patients requiring additional analgesia beyond patient-controlled analgesia |
24 hours
|
|
Incidence of postoperative nausea and/or vomiting
Délai: 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV. |
24 hours postoperatively
|
|
Propofol consumption
Délai: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Area under the numeric rating scale-time curve
Délai: 0 to 24 hours postoperatively
|
The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden. |
0 to 24 hours postoperatively
|
|
Comprehensive Complication Index
Délai: Up to 30 days postoperatively
|
Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity. |
Up to 30 days postoperatively
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SPSIPITM1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .